1. Serum Cytokine Changes in a Patient with Chronic Pulmonary Aspergillosis Overlapping with Allergic Bronchopulmonary Aspergillosis.
- Author
-
Tsukamoto Y, Ito Y, Obase Y, Takazono T, Nakada N, Ashizawa N, Hirayama T, Takeda K, Ide S, Iwanaga N, Tashiro M, Hosogaya N, Fukahori S, Fukushima C, Yanagihara K, Izumikawa K, and Mukae H
- Subjects
- Humans, Chronic Disease, Antifungal Agents therapeutic use, Male, Middle Aged, Aspergillosis, Allergic Bronchopulmonary blood, Aspergillosis, Allergic Bronchopulmonary drug therapy, Aspergillosis, Allergic Bronchopulmonary diagnosis, Aspergillosis, Allergic Bronchopulmonary complications, Pulmonary Aspergillosis blood, Pulmonary Aspergillosis diagnosis, Pulmonary Aspergillosis drug therapy, Pulmonary Aspergillosis complications, Cytokines blood, Voriconazole therapeutic use
- Abstract
Allergic bronchopulmonary aspergillosis (ABPA) and chronic pulmonary aspergillosis (CPA) are diseases caused by Aspergillus infection, and CPA can develop from ABPA in some cases. We herein report a patient with CPA overlapping with ABPA. Serum cytokine levels were evaluated at 4 time points: the ABPA diagnosis, CPA diagnosis, 6 months after the start of voriconazole (VRCZ), and 12 months after re-administration of VRCZ. Interleukin (IL)-13 levels decreased upon glucocorticoid treatment, whereas IL-25 and IL-33 levels decreased rapidly with the initiation of antifungals. Early antifungal therapy may be important to control disease progression and prevent CPA overlap.
- Published
- 2024
- Full Text
- View/download PDF